Akeso secures China NMPA authorisation for ivonescimab combo
Summit Therapeutics’ partner Akeso has secured China’s NMPA authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous NSCLC patients.
Read the full article on the original site.
Read Full Article